Figure 3 — Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses

Research Paper|Volume 16, Issue 10|pp. 8772–8809

Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses

Back to articleFigure 3(3 of 14)

100%

Figure 3.Construction of a metabolic pathway-pair score (MPPS)-based prognostic model. (A) The univariable Cox regression analysis of metabolic pathway pairs. (B, C) Determination of the number of metabolic pathway pairs by the LASSO regression analysis. (D) The multivariable Cox regression analysis of metabolic pathway pairs. (E) Principal Component Analysis of the high- and low-risk groups. (F) The Kaplan-Meier analysis of the high- and low-risk groups in TCGA-LUAD cohort and GEO validation cohorts. OS: overall survival; PFS: progression-free survival. The survival analysis was tested by log-rank test.